Latest fund size
$93.4M
Announced
September 28, 2026
Global HQ
France
Members only
Check size
$2M - $20M
Members only
Stage focus
Pre-Seed, Seed, Series A, Series B, Growth
Members only
Regions of investment
Europe, North America
Members only
Sofinnova Partners is a leading European venture capital firm specializing in life sciences, with a focus on healthcare and sustainability. Established in 1972 and headquartered in Paris, with additional offices in London and Milan, the firm has supported the growth of over 500 companies over its 50-year history.
Antoine Papiernik, Chairman and Managing Partner
apapiernik@sofinnovapartners.com
Tiziana Rossetti, Principal
trossetti@sofinnovapartners.com
Daniel Sieiro, Senior Associate
dsieiro@sofinnovapartners.com
Ankeet Jethwa, Investor
ajethwa@sofinnovapartners.com
Alex Leech, Partner
aleech@sofinnovapartners.com
Joe Anderson, Partner
janderson@sofinnovapartners.com
Graziano Seghezzi, Partner
gseghezzi@sofinnovapartners.com
Anta Gkelou, Partner
agkelou@sofinnovapartners.com
Guillaume Baxter, Partner
gbaxter@sofinnovapartners.com
Michael Krel, Partner
mkrel@sofinnovapartners.com
Maria Camboni, Partner
gcamboni@sofinnovapartners.com
Edward Kliphuis, Partner
ekliphuis@sofinnovapartners.com
Members only
Names, roles, emails and LinkedIn profiles for the team, plus the fund's website.
Sofinnova Partners invests across the entire life sciences value chain, from seed to later-stage companies.
Their investment strategies encompass early-stage biopharma and medtech startups focusing on groundbreaking therapeutic technologies, as well as later-stage growth opportunities in biotech and medtech companies.
Through its MD Start strategy, the firm creates medtech companies from inception, combining clinical insight, entrepreneurial talent, and operational expertise to address significant unmet medical needs, with hands-on involvement from day one through key clinical and operational milestones.
Members only
What the fund looks for in founders and which sectors it backs.
On September 28, 2026, Sofinnova Partners closed its fourth MD Start fund, Sofinnova MD Start IV, at $93.4M, above target and oversubscribed.
MD Start is Sofinnova's medtech company-creation strategy, launched in 2008 with an initial $9.3M fund; Fund IV is roughly 30% larger than its $71.7M predecessor, MD Start III, which invested in six companies that together raised more than $159.4M in follow-on financing.
The new fund plans to launch six to eight new medtech companies over the next five years, backed by existing and new limited partners.
This follows Sofinnova Partners' broader platform raise of $1.4B across its investment strategies in the year to March 2025, bringing total assets under management across the firm to more than $4.6B.
Members only
Fund size, LPs and track record.
Leadership
Antoine Papiernik serves as Chairman and Managing Partner. The firm comprises over 80 professionals, including 25 investment partners, spanning 24 nationalities across its three European offices.
The Sofinnova MD Start IV fund is led by Anne Osdoit, Cécile Dupont, and Mano Iyer as Partners, with Marion Gasperment as Principal, on the strategy's deal team.
Investment Strategy
The firm acts as a founding and lead investor in early-stage biopharma and medtech startups focusing on groundbreaking therapeutic technologies, partnering with entrepreneurs to develop transformative innovations.
Through MD Start, Sofinnova creates medtech companies from inception rather than backing existing ventures, with its team playing an active, hands-on role in building and supporting each company from day one through key clinical and operational milestones.
Notable Investments
Notable Exits
Over the last decade, Sofinnova Partners has completed nine exits in its portfolio for a total enterprise value of almost $4.6B, including:
Members only
Leadership, investment strategy, notable investments and exits.
